Original articleIndomethacin prophylaxis, patent ductus arteriosus, and the risk of bronchopulmonary dysplasia: Further analyses from the Trial of Indomethacin Prophylaxis in Preterms (TIPP)
Section snippets
Study Population
Infants with birth weights ranging from 500 to 999 g were enrolled in the international TIPP study between January 1996 and March 1998.1 The research ethics boards of all clinical centers in Canada, the United States, Australia, New Zealand, and Hong Kong approved the trial protocol, and written informed consent was obtained from a parent or guardian of each infant. Because infants who died before a postmenstrual age 36 weeks could not develop BPD as defined by the TIPP study protocol, only
Study Cohort
In the indomethacin prophylaxis group, 103 of 601 infants (17%) died before postmenstrual age 36 weeks, compared with 96 of 601 infants (16%) in the placebo group. Of the 1003 survivors who were eligible for the current study, 4 children (2 in each treatment group) had missing BPD data. This left 999 infants in our analysis cohort, of whom 496 were assigned to prophylactic indomethacin and 503 to placebo.
Supplemental Oxygen and Urine Volumes After Indomethacin Prophylaxis and Placebo
Figure 1 shows that indomethacin prophylaxis significantly increased the need for
Discussion
Further analysis of the TIPP database reveals that indomethacin prophylaxis increased the need for supplemental oxygen from day 3 to at least day 7 of life. Indomethacin prophylaxis also decreased urine volumes during the first 4 days of life and reduced weight loss by the end of the first week. We explored whether one or both of these harmful drug effects may explain why indomethacin prophylaxis does not alter the incidence of BPD, despite reducing the incidence of PDA. We began this
References (15)
Increased risk of bronchopulmonary dysplasia in infants with patent ductus arteriosus
J Pediatr
(1979)- et al.
Changing trends in the epidemiology and pathogenesis of neonatal chronic lung disease
J Pediatr
(1995) - et al.
Pulmonary hypertension after ibuprofen prophylaxis in very preterm infants
Lancet
(2002) - et al.
Ibuprofen prophylaxis in preterm neonates
Lancet
(2002) - et al.
Pulmonary prostacyclin is associated with less severe respiratory distress in preterm infants
Early Hum Dev
(2002) - et al.
Effects of dexamethasone and indomethacin on elastase, alpha 1-proteinase inhibitor, and fibronectin in bronchoalveolar lavage fluid from neonates
J Pediatr
(1988) - et al.
Early versus late indomethacin treatment for patent ductus arteriosus in premature infants with respiratory distress syndrome
J Pediatr
(2001)
Cited by (0)
Funded by the Medical Research Council of Canada (grant MT-13288). The US centers were supported in part by NICHD (grants U10 HD21364, U10 HD27851, U10 HD21373, U10 HD27881; M01 RR 00997, U10 HD27880; M01 RR 00070, U10 HD21385, U10 HD27904, and U10 HD34216). The INDOCID PDA was donated by Merck Frosst.
- ⁎
A list of TIPP investigators is available at www.jpeds.com.